• Alias: BYL719
    • An orally bioavailable PI3K inhibitor that specifically inhibits PIK3 in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations; inhibits the PI3Kα isoform and much less strongly the β, δ, and γ isoforms
    • Phase 3 in combination with fulvestrant in PIK3CA-mutated advanced breast cancer (SOLAR-1 study); phase 1b/2 clinical trials in combination studies for ovarian cancer, SCCHN, hormone receptor–positive breast cancer, RAS–or RAF–positive colorectal
    Other topics in Targeted and Immunotherapy Agents